Parasitemia

Summary

Parasitemia (MONDO:0024314) is a disease and 7 clinical trials. Top therapeutic interventions include primaquine, acetaminophen, and pyronaridine. A subtype of parasitic infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	parasitemia
Mondo ID	MONDO:0024314
MeSH	D018512
UMLS	C0242723
MedGen	116650
Anatomy (UBERON)	UBERON:0000178
Is cancer (heuristic)	no

Also known as: Parasitemias

Disease family

This is a subtype of parasitic infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › parasitemia

Related subtypes (16): parasitic Ichthyosporea infectious disease, protozoa infectious disease, helminthiasis, coccidioidomycosis, cryptococcosis, microsporidiosis, Strongylida infectious disease, distomatosis, parasitic myositis, demodicidosis, cutaneous larva migrans, amoebiasis due to Entamoeba histolytica, amoebiasis due to free-living amoebae, parasitic eye infection, parasitic intestinal disorder, parasitic skin disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02909712	PHASE2	COMPLETED	Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
NCT03399318	PHASE2	COMPLETED	Aggressive Antipyretics for Fever Reduction in CNS Malaria
NCT04310085	PHASE1	COMPLETED	Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
NCT05287893	PHASE1	COMPLETED	Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
NCT05979207	PHASE1	COMPLETED	Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
NCT00511589	Not specified	COMPLETED	Chagas Disease Diagnostic - Inconclusive Serology
NCT01784315	Not specified	UNKNOWN	Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PRIMAQUINE	4	3
ACETAMINOPHEN	4	1
PYRONARIDINE	3	1